GSC
IMMX icon

Ground Swell Capital’s Immix Biopharma IMMX Stock Holding History

Ground Swell Capital’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,692
Closed -$19.5K – 74
2023
Q1 		$19.5K Buy
+10,692
New +$23.6K 0.03% 42

Other funds holding IMMX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UB
UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM

Ground Swell Capital's IMMX Position: Q2 2023 in Review

Ground Swell Capital sold out of Immix Biopharma (IMMX) in Q2 2023, closing a stake of 10,692 shares — an estimated $19.5K sold.

Ground Swell Capital first reported a position in IMMX in Q1 2023 and held it in 1 quarter. The position peaked at $19.5K in Q1 2023. 18 funds tracked by Wall St. Rank hold IMMX as of Q2 2023.

  • Ground Swell Capital reported no remaining Immix Biopharma position as of Q2 2023 after selling out during the quarter.
  • Ground Swell Capital sold 10,692 Immix Biopharma shares in Q2 2023, an estimated $19.5K.
  • Ground Swell Capital first reported a position in Immix Biopharma in Q1 2023 and held it in 1 quarter.
  • Ground Swell Capital's Immix Biopharma position peaked at $19.5K in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2023.

Based on Ground Swell Capital's 13F filing for Q2 2023, filed 10 Aug 2023.